The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticariaTorsten Zuberbier, Marcus Maurer, Werner Aberer et al.|Allergy|2018Cited by 1.4k
The <scp>EAACI</scp>/<scp>GA</scp><sup>2</sup><scp>LEN</scp>/<scp>EDF</scp>/<scp>WAO</scp> Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and updateTorsten Zuberbier, Marcus Maurer, Werner Aberer et al.|Allergy|2014Cited by 1.2k
Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATEMarc Humbert, K. Surrey, Richard Beasley et al.|Allergy|2004Cited by 1.1k
Efficacy and safety of a recombinant anti‐immunoglobulin E antibody (omalizumab) in severe allergic asthmaStephen T. Holgate, А. Г. Чучалин, Jean‐Louis Hébert et al.|Clinical & Experimental Allergy|2004Cited by 520
New Formula for Predicting Mean Pulmonary Artery Pressure Using Systolic Pulmonary Artery PressureD. S. Chemla, Philippe Hervé, Vincent Castelain et al.|CHEST Journal|2004Cited by 497